Results 31 to 40 of about 28,066 (219)

PCSK9 Inhibition could be Effective for Acute Myocardial Infarction.

, 2022
In this review, we explore the role of PCSK9 and the inhibition of PCSK9 in patients after acute myocardial infarction (MI). Despite the implementation of evidencebased therapies to improve outcomes, one-year mortality remains at 12-15%, and there is ...
Gencer, Baris, Mach, François
core   +1 more source

Naturalne inhibitory PCSK9 — przegląd substancji o możliwym wpływie na PCSK9 [PDF]

, 2021
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein discovered in 2003 and playing an important role in lipoprotein metabolism. The main function of PCSK9 is to regulate the number of low-density lipoprotein (LDL) receptors on the surface ...
Filipiak, Krzysztof J.; Uczelnia Medyczna im. Marii Skłodowskiej-Curie w Warszawie, Poland, Surma, Stanisław; Wydział Nauk Medycznych w Katowicach, Śląski Uniwersytet Medyczny w Katowicach, Medyków 18, 40-752 Katowice, Poland; Klub Młodych Hipertensjologów, Polskie Towarzystwo Nadciśnienia Tętniczego, Poland   +1 more
core   +1 more source

Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody[S]

Journal of Lipid Research, 2015
Lilly PCSK9 antibody LY3015014 (LY) is a monoclonal antibody (mAb) that neutralizes proprotein convertase subtilisin-kexin type 9 (PCSK9). LY decreases LDL cholesterol in monkeys and, unlike other PCSK9 mAbs, does not cause an accumulation of intact ...
Krista M. Schroeder, Thomas P. Beyer, Ryan J. Hansen, Bomie Han, Richard T. Pickard, Victor J. Wroblewski, Mark C. Kowala, Patrick I. Eacho   +7 more
doaj   +1 more source

Correlation between plasma proprotein convertase subtilisin/kexin type 9 and blood lipids in patients with newly diagnosed primary nephrotic syndrome

Renal Failure, 2020
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a major post-transcriptional regulator of low-density lipoprotein receptor degradation. Recently, PCSK9 was shown to be overexpressed by liver cells in rats with proteinuria.
Huaying Shen, Sheng Feng, Ying Lu, Linsen Jiang, Tingting Yang, Zhi Wang   +5 more
doaj   +1 more source

PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy

Biomolecules, 2022
Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a key regulator of low-density lipoprotein (LDL) metabolism involved in the degradation of the low-density lipoprotein receptor (LDLR) through complex mechanisms.
Arianna Toscano, Maria Cinquegrani, Michele Scuruchi, Antonino Di Pino, Salvatore Piro, Viviana Ferrara, Carmela Morace, Alberto Lo Gullo, Egidio Imbalzano, Francesco Purrello, Giovanni Squadrito, Roberto Scicali, Giuseppe Mandraffino   +12 more
doaj   +1 more source

Loss of hepatic SMLR1 causes hepatosteatosis and protects against atherosclerosis due to decreased hepatic VLDL secretion

Hepatology, EarlyView., 2022
The role of SMLR1 in lipid metabolism (high fat + cholesterol diet in mice) Abstract Background and Aims The assembly and secretion of VLDL from the liver, a pathway that affects hepatic and plasma lipids, remains incompletely understood. We set out to identify players in the VLDL biogenesis pathway by identifying genes that are co‐expressed with the ...
Willemien van Zwol, Antoine Rimbert, Justina C. Wolters, Marieke Smit, Vincent W. Bloks, Niels J. Kloosterhuis, Nicolette C. A. Huijkman, Mirjam H. Koster, Umesh Tharehalli, Simon M. de Neck, Colin Bournez, Marceline M. Fuh, Jeroen Kuipers, Sujith Rajan, Alain de Bruin, Henry N. Ginsberg, Gerard J. P. van Westen, M. Mahmood Hussain, Ludger Scheja, Joerg Heeren, Philip Zimmerman, Bart van de Sluis, Jan Albert Kuivenhoven   +22 more
wiley   +1 more source

Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome

Frontiers in Medicine, 2022
BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that is a mediator of the immune response to sepsis. PCSK9 is also highly expressed in pneumocytes and pulmonary endothelial cells.
Thomas S. Metkus, Bo Soo Kim, Steven R. Jones, Seth S. Martin, Steven P. Schulman, Thorsten M. Leucker   +5 more
doaj   +1 more source

Small molecules as inhibitors of PCSK9: current status and future challenges [PDF]

, 2019
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in regulating lipoprotein metabolism by binding to low-density lipoprotein receptors (LDLRs), leading to their degradation.
Zhu, Zheying, Shanshan Luo, Jinyi Xu, Luo, Shanshan, Shengtao Xu, Zheying Zhu, Xu, Shengtao, Xu, Jinyi   +7 more
core   +1 more source

Effects of PCSK9 inhibitors on metabolic-associated fatty liver disease: a short review

, 2023
Metabolic-associated fatty liver disease (MAFLD), previously known as non-alcoholic fatty liver disease, is a significant epidemiological problem and a well-known cardiovascular risk factor.
Paweł Głuszak, Ewelina Jakielska, Wiesław Bryl, Marta Walczak   +3 more
core   +1 more source

Assessing the functional consequence of loss of function variants using electronic medical record & Large-Scale Genomics Consortium Efforts

Frontiers in Genetics, 2014
Estimates from large scale genome sequencing studies indicate that each human carries up to 20 genetic variants that are predicted to results in loss of function (LOF) of protein-coding genes.
Patrick eSleiman, Jonathan eBradfiled, Frank eMentch, Berta eAlmoguera, John eConnolly, Hakon eHakonarson   +5 more
doaj   +1 more source